-transparent.png){kind=logo}
We generated a panel of 10 murine monoclonal antibodies (MAbs) that recognize human complement fragment C5a. These MAbs were characterized for their ability to immunoprecipitate 125I-labeled C5a, bind C5a in solid-phase enzyme immunoassay, and block 125I-labeled C5a binding to polymorphonuclear leukocytes. Four of these MAbs had affinity constants for C5a in the 1 X 10(9) to 3 X 10(9) M-1 range. These MAbs blocked C5a-induced neutrophil polarization and chemiluminescence. They blocked the ability of passively administered C5a to cause neutropenia in rabbits. These anti-C5a neutralizing MAbs may have potential therapeutic use in states of complement activation.
Related Publications
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
August 1987,
Hybridoma,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
January 2018,
PloS one,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
October 1993,
Clinical biochemistry,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
February 1986,
The Journal of biological chemistry,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
February 1996,
The Tohoku journal of experimental medicine,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
November 1989,
Experimental cell research,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
November 1991,
Infection and immunity,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
March 1998,
Blood,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
June 1992,
European journal of immunology,
J W Larrick, and
J Wang, and
B M Fendly, and
D E Chenoweth, and
S L Kunkel, and
T Deinhart
March 1990,
The Journal of general virology,
